These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. The winning formulation: the development of paclitaxel in pancreatic cancer. Ma WW; Hidalgo M Clin Cancer Res; 2013 Oct; 19(20):5572-9. PubMed ID: 23918602 [TBL] [Abstract][Full Text] [Related]
30. Mesothelin-targeted immunotoxin RG7787 has synergistic anti-tumor activity when combined with taxanes. Kolyvas E; Rudloff M; Poruchynsky M; Landsman R; Hollevoet K; Venzon D; Alewine C Oncotarget; 2017 Feb; 8(6):9189-9199. PubMed ID: 27999204 [TBL] [Abstract][Full Text] [Related]
31. Targeting ZFP64/GAL-1 axis promotes therapeutic effect of nab-paclitaxel and reverses immunosuppressive microenvironment in gastric cancer. Zhu M; Zhang P; Yu S; Tang C; Wang Y; Shen Z; Chen W; Liu T; Cui Y J Exp Clin Cancer Res; 2022 Jan; 41(1):14. PubMed ID: 34996504 [TBL] [Abstract][Full Text] [Related]
32. Safety and efficacy evaluation of albumin-bound paclitaxel. Cecco S; Aliberti M; Baldo P; Giacomin E; Leone R Expert Opin Drug Saf; 2014 Apr; 13(4):511-20. PubMed ID: 24559090 [TBL] [Abstract][Full Text] [Related]
33. A phase II trial of nab-Paclitaxel as second-line therapy in patients with advanced pancreatic cancer. Hosein PJ; de Lima Lopes G; Pastorini VH; Gomez C; Macintyre J; Zayas G; Reis I; Montero AJ; Merchan JR; Rocha Lima CM Am J Clin Oncol; 2013 Apr; 36(2):151-6. PubMed ID: 22307213 [TBL] [Abstract][Full Text] [Related]
34. Impact of Nab-Paclitaxel-based Second-line Chemotherapy in Metastatic Pancreatic Cancer. Dadi N; Stanley M; Shahda S; O'Neil BH; Sehdev A Anticancer Res; 2017 Oct; 37(10):5533-5539. PubMed ID: 28982867 [TBL] [Abstract][Full Text] [Related]
35. Initial testing (stage 1) of the tubulin binding agent nanoparticle albumin-bound (nab) paclitaxel (Abraxane(®)) by the Pediatric Preclinical Testing Program (PPTP). Houghton PJ; Kurmasheva RT; Kolb EA; Gorlick R; Maris JM; Wu J; Tong Z; Arnold MA; Chatterjee M; Williams TM; Smith MA Pediatr Blood Cancer; 2015 Jul; 62(7):1214-21. PubMed ID: 25809532 [TBL] [Abstract][Full Text] [Related]
36. Combination therapy with Nab-paclitaxel and the interleukin-15 fused with anti-human serum albumin nanobody as a synergistic treatment for colorectal cancer. Wu L; Wang W; Tian J; Qi C; Cai Z; Yan W; Xuan S; Shang A Bioengineered; 2022 Jan; 13(1):1942-1951. PubMed ID: 35019820 [TBL] [Abstract][Full Text] [Related]
37. Stromal expression of SPARC in pancreatic adenocarcinoma. Neuzillet C; Tijeras-Raballand A; Cros J; Faivre S; Hammel P; Raymond E Cancer Metastasis Rev; 2013 Dec; 32(3-4):585-602. PubMed ID: 23690170 [TBL] [Abstract][Full Text] [Related]
39. nab-paclitaxel: a novel formulation of taxane for treatment of breast cancer. Vishnu P; Roy V Womens Health (Lond); 2010 Jul; 6(4):495-506. PubMed ID: 20597612 [TBL] [Abstract][Full Text] [Related]
40. Preclinical investigation of nanoparticle albumin-bound paclitaxel as a potential treatment for adrenocortical cancer. Demeure MJ; Stephan E; Sinari S; Mount D; Gately S; Gonzales P; Hostetter G; Komorowski R; Kiefer J; Grant CS; Han H; Von Hoff DD; Bussey KJ Ann Surg; 2012 Jan; 255(1):140-6. PubMed ID: 22156929 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]